About This Publication
The Peptide Reviewer is an independent review desk that scores vendor claims against published science. Here is exactly how we work.
The Peptide Reviewer is an editorially independent publication that evaluates peptide vendors and research compounds using primary sources: PubMed-indexed studies, ClinicalTrials.gov records, and FDA communications. Content is educational only, not medical advice, and many compounds covered are research chemicals not approved for human use by the FDA.
Who Is Behind This Site?
The Peptide Reviewer was founded to fill a specific gap: most peptide content online is written by sellers, affiliates, or anonymous bloggers with no stated sourcing standards. This publication operates as a consumer-protection journalism desk. Articles are written by a named senior staff writer with a background in science journalism and reviewed by a named medical reviewer before publication. Both names appear on every article they touch.
We do not sell peptides. We do not manufacture them. We do not hold equity in any vendor we cover. When a vendor sends us a certificate of analysis or a product sample for review, that does not buy favorable coverage. Our revenue model, if any commercial relationship exists, is disclosed in line with FTC guidelines on endorsements and testimonials. If a piece contains an affiliate relationship, it is labeled at the top of the article, not buried in a footer.
How We Evaluate Evidence
Every factual claim in this publication is tied to a source tier, and we name the tier explicitly in the text. We do not treat a rat study and a randomized controlled trial as equivalent, and we do not let you assume they are.
Our four tiers, in descending weight, are: human randomized controlled trials (RCTs), which are the strongest evidence for any claim about human outcomes; small or uncontrolled human studies, which can suggest signals but cannot establish causation; animal studies, which are preclinical and may or may not translate to humans; and in-vitro (cell culture) studies, which are the earliest stage of research and the furthest from clinical application. The majority of peptide research sits in the animal or in-vitro tiers. We say so plainly, every time.
Primary sources are PubMed-indexed journal abstracts and full texts, ClinicalTrials.gov trial registrations, and official FDA communications. We do not cite vendor white papers, press releases, or secondary health blogs as evidence. Every URL we publish is verified before the article goes live. A dead or invented link is treated as a factual error and triggers a correction.
- Human RCT: highest weight, named as such in every article
- Small or uncontrolled human study: noted as preliminary human evidence
- Animal study: noted as preclinical, translation to humans unconfirmed
- In-vitro study: noted as earliest-stage research only
What This Site Is and Is Not
All content on The Peptide Reviewer is educational and informational. Nothing here is medical advice, and nothing here should be read as a protocol, instruction, or recommendation for taking any compound. Readers with health questions should consult a licensed medical professional.
Many compounds discussed on this site are research chemicals. They are not approved by the FDA for human use. Where a compound has an approved pharmaceutical form, such as semaglutide sold as Wegovy or Ozempic, or bremelanotide sold as Vyleesi, we attribute the approval specifically to the branded drug and note that research-chemical versions carrying the same name are not approved. We do not use the existence of an approved drug to imply that an unapproved research compound carries equivalent regulatory status.
We do not make disease-treatment claims. We do not use phrases like 'proven to treat' or 'cures.' When a study shows a statistically significant result, we report the result, the sample size, the journal, and the year. Readers can then weigh that evidence themselves.
Corrections and Updates
Science changes. Vendor COAs change. When a reader or reviewer identifies a factual error, we correct it with a dated correction notice at the top of the affected article. We do not silently edit errors away. If new research materially changes the evidence picture for a compound or a vendor, the article is updated and the update date is shown alongside the original publication date.
Correction requests can be sent to our editorial contact address listed in the site footer. We review every submission and respond to substantive ones. Vendors who dispute a review finding are welcome to submit a formal response with supporting documentation. We will review the documentation and note any verified changes in the article.
Frequently asked questions
Does The Peptide Reviewer accept payment from vendors it reviews?
No. Vendors do not pay for coverage, positive or negative. Any commercial relationship, such as an affiliate link, is disclosed at the top of the article where it appears, per FTC endorsement guidelines.
Is the content on this site medical advice?
No. All content is educational and informational only. Many compounds discussed are research chemicals not approved for human use. Readers should consult a licensed medical professional before making any health-related decisions.
How does this site handle research compounds that share a name with an FDA-approved drug?
We attribute FDA approvals specifically to the branded pharmaceutical product. Research-chemical versions carrying the same compound name are not approved by the FDA, and we do not imply otherwise. The approval of a branded drug does not extend to unregulated research chemicals sold under a similar name.
Sources
Sources are listed most recent first. Cited studies are peer-reviewed unless noted.
Educational and informational content only. This is not medical advice, diagnosis, or treatment. The compounds discussed are research compounds not approved by the FDA or any equivalent authority for human use outside prescribed contexts. Always consult a licensed clinician before any health decision.
